Furthermore, recent evidence highlighting prognostic differences among distinct molecular subtypes of glioma, including those with 1p/19q codeletion, isocitrate dehydrogenase (IDH) mutations, and differential MGMT methylation status [82], raises the possibility of subtype specific differences in both glioma cell and TAM expression profiles, and therefore in the composition of the tumor microenvironment; such discrepancies remain to be explored. The gene discussed is MGMT; the disease is glioma.